The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life...
The Asabys Innvierte Tech Transfer FCRE fund, specialised in biotechnology and medical technologies, will invest in the creation and development of innovative companies in the field of deep-tech appli...
Orikine Bio develops therapies capable of 'reprogramming' the immune system, similar to how software engineers rewrite faulty code to repair computer systems.
Oriva Therapeutics, a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women, announced today its incorporation, as well...
The round was led by French investment firm Quadrille Capital and included the participation of Asabys Partners, Cofides, the Institut Català de Finances, and Endeavor Catalyst. Existing shareholders...
Ona Therapeutics is a pioneer in the development of first-in-class antibody-drug conjugates (ADCs) that leverage the molecular basis of advanced cancer. Through collaboration with academic and clinica...
As part of this agreement, the Alta Life Sciences Spain I FCR fund will be co-managed by both firms. Asabys’ founding partners, Clara Campàs and Josep Sanfeliu, will join the Fund’s Investment Co...
The Series B financing was co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB ...
The round was co-led by prominent investors Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. The financing round also had strong participation from existing investors Asabys...
Nature, the world's leading scientific journal, has spotlighted three Barcelona-based biotech startups, Ona Therapeutics, Nuage Therapeutics, and SpliceBio, in a recent article highlighting Spain's bu...
The oversubscribed financing was co-led by Novo Holdings and Jeito Capital, supported by existing investors Asabys Partners, who led an initial EUR 17.5 million closing in 2024, Eli Lilly and Company,...
Con un impacto social y económico significativo, el ictus representa un desafío crítico a nivel global. Según datos recientes, el ictus afectará al 25% de los adultos mayores de 25 años a lo lar...